Darifenacin is a selective M3 muscarinic acetylcholine receptor antagonist used to treat overactive bladder symptoms such as urinary urgency, frequency, and urge incontinence. This category provides comprehensive… Read more
![Chemical structure of (3S)-1-[2-(3-Ethenyl-4-hydroxyphenyl)ethyl]-α,α-diphenyl-3-pyrrolidineacetamide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1048979-09-4-3S-1-2-3-Ethenyl-4-hydroxyphenylethyl-diphenyl-3-pyrrolidineacetamide.png&w=3840&q=75)









![Chemical structure of (S)-2-{1-[2-(2,3-Dihydrobenzofuran-5-yl)ethyl]pyrrolidin-3-yl}2,2-diphenyl Acetic Acid](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1048979-16-3-S-2-1-2-23-Dihydrobenzofuran-5-ylethylpyrrolidin-3-yl22-diphenyl-Acetic-Acid.png&w=3840&q=75)
































Darifenacin is a selective M3 muscarinic acetylcholine receptor antagonist used to treat overactive bladder symptoms such as urinary urgency, frequency, and urge incontinence. This category provides comprehensive reference standards for the parent drug, alongside its synthetic intermediates, degradation products, metabolites, and stable isotope labelled compounds. Pharmaceutical laboratories rely on these materials for critical analytical functions, including impurity profiling, method validation, and rigorous quality control protocols. By providing accurately characterized reference standards, these compounds support pharmaceutical development through forced degradation studies and stability testing in accordance with international regulatory guidelines. The inclusion of stable isotope labelled compounds facilitates high-precision quantification and internal standard applications during mass spectrometry-based analysis. These materials ensure that the safety and efficacy profiles of the drug product are thoroughly characterized throughout the manufacturing process and regulatory submission lifecycle.